Resources from the same session
Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS
Presenter: Nathan Cherny
Session: 5-year impact of new registered indications on the ESMO-MCBS
Resources:
Slides
Webcast
ICI landscape in solid tumours: what are the scores, are there differences and why?
Presenter: Luís Castelo-Branco
Session: 5-year impact of new registered indications on the ESMO-MCBS
Resources:
Slides
Webcast